Results 21 to 30 of about 41,743 (197)

Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism

Pharmaceutics, 2019
This study investigated the pharmacokinetics of tofacitinib in rats and the effects of first-pass metabolism on tofacitinib pharmacokinetics. Intravenous administration of 5, 10, 20, and 50 mg/kg tofacitinib showed that the dose-normalized area under the
Ji Sang Lee, So Hee Kim
doaj   +1 more source

Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial

Transplantation Direct, 2018
Background. Tofacitinib is an oral Janus kinase inhibitor. This open-label, long-term extension (LTE) study (NCT00658359) evaluated long-term tofacitinib treatment in stable kidney transplant recipients (n = 178) posttransplant. Methods.
Stephan Busque, MD, MSc, FRCSC, Flavio G. Vincenti, MD, Helio Tedesco Silva, MD, Philip J. O’Connell, MD, Atsushi Yoshida, MD, John J. Friedewald, MD, Steven M. Steinberg, MD, Klemens Budde, MD, Emine N. Broeders, MD, Yon Su Kim, MD, Carolyn M. Hahn, BA, Huihua Li, MS, Gary Chan, PharmD   +12 more
doaj   +1 more source

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats

Pharmaceutics, 2021
Fungal infections are prevalent in patients with immune diseases. Voriconazole, a triazole antifungal drug, inhibits the cytochromes CYP3A4 and CYP2C, and tofacitinib, a Janus kinase inhibitor for the treatment of rheumatoid arthritis, is metabolized by ...
Ji-Sang Lee, Hyo-Sung Kim, Yong-Seob Jung, Hyeon-Gyeom Choi, So-Hee Kim   +4 more
doaj   +1 more source

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies [PDF]

Intestinal Research, 2018
Background/AimsTofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily ...
Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi   +10 more
doaj   +1 more source

Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study

Scientific Reports, 2023
We aimed to determine the risk of herpes zoster (HZ) in Korean rheumatoid arthritis (RA) patients on tofacitinib compared with tumor necrosis factor inhibitor (TNFi) treatment.
Yeo-Jin Song, Soo-Kyung Cho, Hyoungyoung Kim, Hye Won Kim, Eunwoo Nam, Ja-Young Jeon, Hyun-Jeong Yoo, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Sang-Cheol Bae, Dae Hyun Yoo, Yoon-Kyoung Sung   +12 more
doaj   +1 more source

Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis, but Does Not Directly Affect Chondro- and Osteogenesis

Immuno, 2021
Entheseal spinal inflammation and new bone formation with progressive ankylosis may occur in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Tobias Russell, Hannah Rowe, Charlie Bridgewood, Richard J. Cuthbert, Abdulla Watad, Darren Newton, Elena Jones, Dennis McGonagle   +7 more
doaj   +1 more source

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

ACR Open Rheumatology, 2020
Objective Metabolic syndrome (MetS) is a cluster of concurrent risk factors for cardiovascular disease and type 2 diabetes. This post hoc analysis explored key efficacy and safety endpoints in patients with psoriatic arthritis (PsA) and MetS treated with
Christopher T. Ritchlin, Jon T. Giles, Alexis Ogdie, Juan J. Gomez‐Reino, Philip Helliwell, Pamela Young, Cunshan Wang, Joseph Wu, Ana Belén Romero, John Woolcott, Lori Stockert   +10 more
doaj   +1 more source

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial

Rheumatology and Therapy, 2023
Introduction This post hoc analysis of phase 2 trial data assessed the efficacy of tofacitinib on magnetic resonance imaging (MRI) outcomes with the detailed anatomy-based Canada–Denmark (CANDEN) MRI scoring system and evaluated tofacitinib suppression ...
Mikkel Østergaard, Joseph Wu, Lara Fallon, Sarah P. Sherlock, Cunshan Wang, Dona Fleishaker, Keith S. Kanik, Walter P. Maksymowych   +7 more
doaj   +1 more source

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Therapeutic Advances in Gastroenterology, 2021
Introduction: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with EIMs,
David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo G. Kotze, Marcia Pinheiro, Rajiv Mundayat, Eric Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan R. Vavricka, Gary R. Lichtenstein   +11 more
doaj   +1 more source

Tofacitinib Decreases Autophagy of Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients

Frontiers in Pharmacology, 2022
The pathway of Janus tyrosine kinases (JAKs) has a central role in the pathogenesis of Rheumatoid Arthritis (RA) by regulating multiple immune functions and cytokine production.
M. Vomero, M. Vomero, M. Caliste, C. Barbati, M. Speziali, A. I. Celia, F. Ucci, C. Ciancarella, E. Putro, T. Colasanti, G. Buoncuore, E. Corsiero, M. Bombardieri, F. R. Spinelli, F. Ceccarelli, F. Conti, C. Alessandri   +16 more
doaj   +1 more source